Agile Therapeutics, Inc. Stock price

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets 03:58:29 2024-03-28 pm EDT 5-day change 1st Jan Change
0.34 USD -8.11% Intraday chart for Agile Therapeutics, Inc. -39.39% -82.56%
Sales 2023 19.59M Sales 2024 * 36.84M Capitalization 2.22M
Net income 2023 -14M Net income 2024 * 5M EV / Sales 2023 0.25 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.06 x
P/E ratio 2023
-0.29 x
P/E ratio 2024 *
0.44 x
Employees 22
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.11%
1 week-39.39%
Current month-57.23%
1 month-55.76%
3 months-82.29%
6 months-84.40%
Current year-82.56%
More quotes
1 week
0.20
Extreme 0.2
0.61
1 month
0.20
Extreme 0.2
0.88
Current year
0.20
Extreme 0.2
1.98
1 year
0.20
Extreme 0.2
12.15
3 years
0.20
Extreme 0.2
4 420.00
5 years
0.20
Extreme 0.2
9 530.40
10 years
0.20
Extreme 0.2
26 380.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 04-01-31
Director of Finance/CFO 57 10-11-30
Chief Tech/Sci/R&D Officer 58 20-08-16
Members of the board TitleAgeSince
Chief Executive Officer 65 04-01-31
Director/Board Member 68 16-07-27
Director/Board Member 67 14-11-17
More insiders
Date Price Change Volume
24-03-28 0.34 -8.11% 293,428
24-03-27 0.37 +10.78% 468,809
24-03-26 0.334 -44.54% 1,714,416
24-03-25 0.6022 +10.11% 2,983,826
24-03-22 0.5469 -2.51% 423,892

Delayed Quote OTC Markets, March 28, 2024 at 03:58 pm EDT

More quotes
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company's sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company's transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.34
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Agile Therapeutics, Inc. - OTC Markets